These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

676 related articles for article (PubMed ID: 26718488)

  • 1. Co-Delivery of Epirubicin and siRNA Using Functionalized Mesoporous Silica Nanoparticles Enhances In vitro and In vivo Drug Efficacy.
    Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Abnous K; Malaekeh-Nikouei B
    Curr Drug Deliv; 2016; 13(7):1176-1182. PubMed ID: 26718488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surface functionalized mesoporous silica nanoparticles as an effective carrier for epirubicin delivery to cancer cells.
    Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Xue M; Amin M; Shahtahmassebi N; Malaekeh-Nikouei B
    Eur J Pharm Biopharm; 2015 Jan; 89():248-58. PubMed ID: 25511563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amphiphilic hyperbranched polyester coated rod mesoporous silica nanoparticles for pH-responsive doxorubicin delivery.
    Bafkary R; Ahmadi S; Fayazi F; Karimi M; Fatahi Y; Ebrahimi SM; Atyabi F; Dinarvand R
    Daru; 2020 Jun; 28(1):171-180. PubMed ID: 32006342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Redox-responsive mesoporous silica nanoparticles: a physiologically sensitive codelivery vehicle for siRNA and doxorubicin.
    Ma X; Teh C; Zhang Q; Borah P; Choong C; Korzh V; Zhao Y
    Antioxid Redox Signal; 2014 Aug; 21(5):707-22. PubMed ID: 23931896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid nanoparticle-based co-delivery of epirubicin and BCL-2 siRNA for enhanced intracellular drug release and reversing multidrug resistance.
    Yu M; Han S; Kou Z; Dai J; Liu J; Wei C; Li Y; Jiang L; Sun Y
    Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):323-332. PubMed ID: 28393563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MUC1 aptamer-conjugated mesoporous silica nanoparticles effectively target breast cancer cells.
    Hanafi-Bojd MY; Moosavian Kalat SA; Taghdisi SM; Ansari L; Abnous K; Malaekeh-Nikouei B
    Drug Dev Ind Pharm; 2018 Jan; 44(1):13-18. PubMed ID: 28832225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved anticancer efficacy of epirubicin by magnetic mesoporous silica nanoparticles: in vitro and in vivo studies.
    Ansari L; Jaafari MR; Bastami TR; Malaekeh-Nikouei B
    Artif Cells Nanomed Biotechnol; 2018; 46(sup2):594-606. PubMed ID: 29688064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery.
    Ma X; Zhao Y; Ng KW; Zhao Y
    Chemistry; 2013 Nov; 19(46):15593-603. PubMed ID: 24123533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The properties of mesoporous silica nanoparticles functionalized with different PEG-chain length via the disulfide bond linker and drug release in glutathione medium.
    Xie Z; Gong H; Liu M; Zhu H; Sun H
    J Biomater Sci Polym Ed; 2016; 27(1):55-68. PubMed ID: 26540096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surface decorated nanoparticles as surrogate carriers for improved transport and absorption of epirubicin across the gastrointestinal tract: Pharmacokinetic and pharmacodynamic investigations.
    Tariq M; Alam MA; Singh AT; Panda AK; Talegaonkar S
    Int J Pharm; 2016 Mar; 501(1-2):18-31. PubMed ID: 26812610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular cleavable poly(2-dimethylaminoethyl methacrylate) functionalized mesoporous silica nanoparticles for efficient siRNA delivery in vitro and in vivo.
    Lin D; Cheng Q; Jiang Q; Huang Y; Yang Z; Han S; Zhao Y; Guo S; Liang Z; Dong A
    Nanoscale; 2013 May; 5(10):4291-301. PubMed ID: 23552843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance.
    Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Cao X; Zhang H
    Mater Sci Eng C Mater Biol Appl; 2018 Mar; 84():108-117. PubMed ID: 29519418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The packaging of siRNA within the mesoporous structure of silica nanoparticles.
    Li X; Xie QR; Zhang J; Xia W; Gu H
    Biomaterials; 2011 Dec; 32(35):9546-56. PubMed ID: 21906804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successfully tailoring the pore size of mesoporous silica nanoparticles: exploitation of delivery systems for poorly water-soluble drugs.
    Jia L; Shen J; Li Z; Zhang D; Zhang Q; Duan C; Liu G; Zheng D; Liu Y; Tian X
    Int J Pharm; 2012 Dec; 439(1-2):81-91. PubMed ID: 23078857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A mesoporous silica nanoparticle--PEI--fusogenic peptide system for siRNA delivery in cancer therapy.
    Li X; Chen Y; Wang M; Ma Y; Xia W; Gu H
    Biomaterials; 2013 Jan; 34(4):1391-401. PubMed ID: 23164421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Effects of Polymer-Surface Decoration on Drug Delivery, Cellular Retention, and Action Mechanisms of Functionalized Mesoporous Silica Nanoparticles.
    You Y; Hu H; He L; Chen T
    Chem Asian J; 2015 Dec; 10(12):2744-54. PubMed ID: 26248202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer-targeted and intracellular delivery of Bcl-2-converting peptide with functional macroporous silica nanoparticles for biosafe treatment.
    Wu Y; Ge P; Xu W; Li M; Kang Q; Zhang X; Xie J
    Mater Sci Eng C Mater Biol Appl; 2020 Mar; 108():110386. PubMed ID: 31923940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polydopamine coated hollow mesoporous silica nanoparticles as pH-sensitive nanocarriers for overcoming multidrug resistance.
    Shao M; Chang C; Liu Z; Chen K; Zhou Y; Zheng G; Huang Z; Xu H; Xu P; Lu B
    Colloids Surf B Biointerfaces; 2019 Nov; 183():110427. PubMed ID: 31408782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unsaturated nitrogen-rich polymer poly(l-histidine) gated reversibly switchable mesoporous silica nanoparticles using "graft to" strategy for drug controlled release.
    Mu S; Liu Y; Wang T; Zhang J; Jiang D; Yu X; Zhang N
    Acta Biomater; 2017 Nov; 63():150-162. PubMed ID: 28873341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macroporous silica nanoparticles for delivering Bcl2-function converting peptide to treat multidrug resistant-cancer cells.
    Xu W; Ge P; Niu B; Zhang X; Liu J; Xie J
    J Colloid Interface Sci; 2018 Oct; 527():141-150. PubMed ID: 29787950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.